Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically-confirmed advanced solid tumor, chronic lymphocytic leukemia, small lymphocytic lymphoma, T-cell prolymphocytic leukemia, Non-Hodgkin Lymphoma or multiple myeloma~* Progressed or not tolerated standard therapy, and no further standard therapy is available~* Archival and screening tumor biopsy~* Eastern Cooperative Oncology Group Performance Status: 0 or 1~* Adequate organ function~Exclusion Criteria:~* Prior cancer-directed modalities or investigational drugs within 4 wks or 5 half lives, whichever is shorter~* Symptomatic brain metastases (prior treatment and stable metastases are allowed)~* Acute or chronic renal disease or pancreatitis~* Diarrhea ≥ Grade 2, impaired gastrointestinal absorption~* Impaired cardiac function~* History of diabetes requiring treatment, glucose \>126 mg/dL, Glycated hemoglobin (HbA1c) ≥6.5%~* Peripheral neuropathy ≥ Grade 2~* Known Human Immunodeficiency Virus (HIV) infection, chronic hepatitis B or C (unless associated with hepatocellular cancer)~* Pregnant, inadequate contraception, breast feeding~* Most concurrent second malignancies~* Part B only: Prior treatment with agents targeting both mammalian target of rapamycin (mTOR) complexes (dual mammalian target of rapamycin complex 1/2 inhibitors) and/or PI3K/AKT pathways. However, prior treatment with isolated target of rapamycin complex 1 (TORC1) inhibitors (eg., rapalogs) is allowed in both parts of this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CC-115 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).